Rx License-Rx

TAB-3488

A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase

The present invention is directed to a synthesis of a dual-target inhibitor of cannabinoid-1 (CB1R) receptor and inducible nitric oxide synthase, and more specifically, to an improved process for synthesis of (S,1E,NE)-N-(1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide. Commercial applications: This new route and process to synthesis S-MRI1867 without chromatography can be easily adapted to GMP manufacture to produce S-MRI1867 for clinical studies and further commercial production. Competitive advantages: This process to produce S-MRI1867 is more time efficient and cost effective. It gives a new version to synthesis the compounds with the core structure similar to S-MRI1867. Source institute: NCATS. Inventors: Huang, Junfeng, Alimardanov, Asaf.

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Cardiometabolic

Indication: Endocrinology

Modality: Small Molecule

Focus tags: Cardiometabolic

Technology tags: Small Molecule, Biomanufacturing

Mechanism:

Development stage: Commercial-Ready

Patent status: Abandoned; Expired; Issued

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Cardiometabolic. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be commercial-ready and is associated with National Institutes of Health. The practical first use case is Endocrinology. Public description: The present invention is directed to a synthesis of a dual-target inhibitor of cannabinoid-1 (CB1R) receptor and inducible nitric oxide synthase, and more specifically, to an improved process for synthesis of.

What is exciting

More mature than a typical academic invention: Prior human, regulatory, or deployment evidence can shorten diligence and make strategic buyers more comfortable.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Indication narrowing plus an outsourced translational evidence package

Negatives / diligence concerns

Adoption and buyer pull must be proven: Commercial-ready tools still need workflow fit, budget owner clarity, reimbursement or procurement logic, and competitive differentiation.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Novartis — Broad modality appetite and academic-origin BD history. Takeda — Translational science focus and partnership-friendly structure. Sanofi — Immunology, rare disease, and platform-technology BD appetite.

Development Strategy to Increase PoS

First indication: Endocrinology

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Indication narrowing plus an outsourced translational evidence package Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Indication narrowing plus an outsourced translational evidence package

Best next experiment: Run the smallest independent study that validates: Prioritize the fastest reimbursable niche and run an IND-enabling package with a specialized CRO.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.